Clinical Trial Update: Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis [Phase 2, Phase 3]

View source ↗

Summary

A double-blind study comparing E3810 tablets (10 mg or 20 mg twice daily) to evaluate efficacy and safety in patients with refractory reflux esophagitis; the Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagitis Reflux
• Gastroesophageal Reflux Disease

Drugs mentioned

• E3810

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Refractory Reflux Esophagitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-04-13